Dcgi Approves Entod Pharma Phase Iii Study Of 0.05 Per Cent Atropine Eye Drops

The Eye Drops Are Used To Treat Eye Problems Like Myopia, Especially In Children, When They Can Clearly See Nearby Objects But Have Problems Seeing Distant Objects. Low-Dose Atropine Has Emerged As An Effective Approach To Slow The Progression Of Myopia In Children And Has Recently Garnered A Lot Of Interest From Ophthalmologists. Entod Pharmaceuticals Has Got The Approval To Carry Out Phase Iii Trials Across India For Their 0.05 Per Cent Atropine Eye Drops From The (Full Form ) Dcgi. This Higher Strength Of Low-Dose Atropine Eye Drops Is Not Available Commercially Globally And Entod Pharmaceuticals Would Be The First Company To Launch This In India Subject To A Successful Demonstration Of Safety And Efficacy In Clinical Studies. "Myatro 0.01 Per Cent Eye Drops Are Used To Treat Eye Problems Like Myopia, Especially In Children, When A Child Can Clearly See Nearby Objects But Has Problems Seeing Distant Objects. Low-Dose Atropine Has Emerged As An Effective Approach To Slow The Progression Of Myopia In Children And Has Recently Garnered A Lot Of Interest From Ophthalmologists. A Recent Lamp (Low-Concentration Atropine For Myopia Progression) Study Published By The American Academy Of Ophthalmology (Aao) Revealed That The 0.05 Per Cent, 0.025 Per Cent, And 0.01 Per Cent Atropine Eye Drops Reduced Myopia Progression And Were Well Tolerated By Children Without Any Adverse Effects. However, Out Of The Three Concentrations, 0.05 Per Cent Atropine Was The Most Effective In Controlling Al Elongation And Se Progression Over A Period Of One Year," A Press Statement Informed. Speaking About The Latest Development, Nikkhil K. Masurkar, Executive Director, Entod Pharmaceuticals, Said, "We Have Already Recruited Several Clinical Research Sites Across India To Start Phase Iii Trial Studies And, Hopefully, We Will Be The First Company In The World To Get Approval For Marketing 0.05 Per Cent Atropine Eye Drops From The Dcgi. Being Market Leaders In Paediatric Ophthalmology Medicine, We Hope This New Therapeutic Addition To The Low-Dose Atropine Range Will Allow Us To Tackle The Menace Of Childhood Myopia In India. Myopia Is The Most Important Cause Of Visual Impairment In Children And, As Per A Study By Aiims, 17 Per Cent Of Children, Or One Out Of Six Children In India Between The Ages Of Five And 15 Years, Are Suffering From Myopia. " "Myopia Is A Growing Concern That Causes An Abnormal Curvature Of The Cornea Or Elongation Of The Eyeball Such That Light No Longer Focuses Directly On The Retina. Excessive Laptop And Smartphone Screen Exposure Times, Particularly Due To Online Homeschooling During The Pandemic, Reduced Outdoor Play, And A Decreased Exposure To Sunlight Have Significantly Increased The Incidence Of Myopia In Young Children, Potentially Leading To Visual Complications Such As Glaucoma, Early Cataract Development, Retinal Detachment, And Myopic Maculopathy. Atropine Eye Drops Are One Of The Most Viable Therapeutic Options Available To Slow Down The Progression Of Myopia Rapidly And Improve A Child'S Vision" Said Dr Namrata Sharma, General Secretary, All India Ophthalmological Society (Aios) She Further Added, "Atropine Treatment Has Now Become Part Of Routine Clinical Practise In India And Shows Real Promise As A Treatment For Controlling Myopia. The Clinical Trials Will Allow Us To Further Understand How Atropine 0.05 Per Cent Can Be Used Effectively With No Side Effects As A Solution For Growing Myopia Concerns Not Only In India But Across The Entire World."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!